Shuttle Pharmaceuticals Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $4.79M
- P/E (TTM)
- –
- Dividend yield
- –
About Shuttle Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Shuttle Pharmaceuticals Holdings, Inc. operates as a pharmaceutical software and drug discovery enterprise centered around Molecule.ai, an artificial intelligence platform acquired in November 2025. The company previously developed clinical-stage therapeutic candidates, notably Ropidoxuridine, prior to initiating a wind-down of its clinical trials. Molecule.ai integrates a unified inference engine, an API-first framework, and modular predictive models to support molecular property prediction, multi-compound comparative analysis, and structured scientific reasoning. These software solutions serve researchers and pharmaceutical research and development teams navigating chemical exploration and early-stage drug design.
The business operates with two full-time employees. Its principal executive offices are situated in Gaithersburg, Maryland, United States. Corporate activities and research infrastructure center around this domestic headquarters location.
Summary of the business section of Shuttle Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Shuttle Pharmaceuticals Holdings, Inc.
- Founded
- 2012
- Headquarters
- Gaithersburg, MD
- Address
- 401 Professional Drive, Suite 260 20879
- Phone
- (240) 403-4212
- Employees
- 2, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Forvis Mazars, LLP, Atlanta, Georgia
Stock & identifiers
- Ticker
- SHPH
- Exchange
- Nasdaq
- IPO date
- Aug 31, 2022
- Shares outstanding
- 5M, Sep 21, 2026
- Public float
- $4.74M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Sep 24, 2026; 1-for-10 reverse, Jun 11, 2026; 1-for-25 reverse, Aug 13, 2025; 1-for-25 reverse, Jun 16, 2025; 1-for-8 reverse, Sep 4, 2024; 1-for-8 reverse, Aug 13, 2024
- SEC CIK
- 1757499
- CUSIP
- 825693500
- ISIN
- US8256935003
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ryan Trasolini | Co-Chief Executive Officer | – |
| Yuying Liang | Chief Financial Officer | – |
| Timothy J. Lorber | Chief Financial Officer | 227,635 |
| Chris Cooper | Interim Co-CEO | – |
| Angel Liriano | Director | 0 |
| Arachchige Sachin Eranga Pathigoda | Director | 0 |
| Adam V. Chambers | Director | 0 |
| Steven M. Richards | Director | 210,004 |
| Joseph Tung | Director | 184,162 |
| George Scorsis | Director | 184,162 |
| Oleh Nabyt | Director | 184,162 |
| Joshua Schafer | Director | 210,004 |
| Milton Brown | Director | 346,617 |
Employees
Headcount reported in annual reports
“As of the date of this Annual Report, we have two full-time employees.”
Corporate history
Events identified from SEC filings